On the basis of existing evidence, this work offers a novel posttranscriptional mechanism by which LRPPRC facilitates tumor progression as well as mediates immune evasion in HCC through elevating m6A modification of PD-L1 mRNA, which might offer a possible strategy for the immunotherapy against HCC via utilizing LRPPRC as a therapeutic target. The gene discussed is LRPPRC; the disease is neoplasm.